A Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis
This study has been completed.
Information provided by:
First received: August 1, 2002
Last updated: June 23, 2005
Last verified: January 2004
The objective of this study is to demonstrate the safety and efficacy of IC14 in the treatment of hospitalized patients with community-acquired pneumonia and sepsis.
Drug: Recombinant Chimeric Monoclonal Antibody
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||A Phase 2 Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis|
Resource links provided by NLM:
Further study details as provided by ICOS Corporation:
Contacts and Locations